This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines
by Zacks Equity Research
Pilgrim's Pride, Exelixis, Synchrony and United Airlines have been highlighted in this Screen of The Week article.
EXEL or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
by Urmimala Biswas
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHSC
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
by Zacks Equity Research
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
by Zacks Equity Research
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study.
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.
EXEL vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
by Urmimala Biswas
Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
by Zacks Equity Research
Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
by Zacks Equity Research
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
by Zacks Equity Research
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.